ReShape Lifesciences Inc
NASDAQ:RSLS
ReShape Lifesciences Inc
Cash from Financing Activities
ReShape Lifesciences Inc
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
ReShape Lifesciences Inc
NASDAQ:RSLS
|
Cash from Financing Activities
$17.6m
|
CAGR 3-Years
244%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
Becton Dickinson and Co
NYSE:BDX
|
Cash from Financing Activities
-$2.3B
|
CAGR 3-Years
-144%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-10%
|
|
Boston Scientific Corp
NYSE:BSX
|
Cash from Financing Activities
$5m
|
CAGR 3-Years
-74%
|
CAGR 5-Years
-68%
|
CAGR 10-Years
N/A
|
|
Stryker Corp
NYSE:SYK
|
Cash from Financing Activities
-$1.6B
|
CAGR 3-Years
-425%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbott Laboratories
NYSE:ABT
|
Cash from Financing Activities
-$7.1B
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-9%
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cash from Financing Activities
$46.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
See Also
What is ReShape Lifesciences Inc's Cash from Financing Activities?
Cash from Financing Activities
17.6m
USD
Based on the financial report for Dec 31, 2023, ReShape Lifesciences Inc's Cash from Financing Activities amounts to 17.6m USD.
What is ReShape Lifesciences Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
12%
Over the last year, the Cash from Financing Activities growth was 461%. The average annual Cash from Financing Activities growth rates for ReShape Lifesciences Inc have been 244% over the past three years , 12% over the past five years .